Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Novartis to Cut 1,960 Jobs in U.S.
8:12 AM MST | January 13, 2012 | Deepti Ramesh
Novartis (Basel, Switzerland) says it plans to restructure the company’s business in the U.S. The restructuring is mainly to respond to the loss of patent exclusivity for Diovan, the market-leading hypertension medication, expected in the U.S. in September 2012, and also because of the expected impact on worldwide sales of Rasilez/Tekturna after Altitude clinical study termination, the company says. The company will restructure its general medicines business in the U.S. market, and as a result, the field force will be reduced by about 1,630 positions and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee